Agreement adds a new preclinical ADC with potential for enhanced anti-tumour activity and best-in-class profile
Takeda will seek an external partner to leverage its cell therapy platform technologies
IND application for EB-003 expected in early 2026
Ascletis announces ultra-long-acting subcutaneous depot maintenance formulation of small molecule GLP-1R agonist ASC30 with 75-Day observed half-life in participants with obesity
Skyhawk Therapeutics enters into an option agreement to grant Merck KGaA, Darmstadt, Germany, exclusive global rights to drug candidates pursued under the collaboration upon option exercise
Upgrades 2025 full-year CDMO sales and margin outlook
Investment will support AstraZeneca’s ambition to reach $80 billion revenue by 2030, with 50% generated in the US
BASF strengthens its commitment to the biopharma and pharmaceutical ingredients industries through a new investment in North America
The collaboration furthers AstraZeneca’s presence in China following the $2.5bn investment in Beijing
The acquisition sets up the foundation for a central hub of GMP value-added services and greater access to new customers in the rapidly growing Biopharma market
Subscribe To Our Newsletter & Stay Updated
